Ankon Technologies, developer of a capsule-based gastric cancer diagnostics system, has received funding from investors including SoftBank's Chinese CVC subsidiary.

China-based oncological diagnostics system developer Ankon Technologies has secured $100m in funding from investors including SBCVC, a corporate venturing vehicle for telecommunications group SoftBank, China Money Network reported today.

SBCVC, SoftBank’s China-focused fund, was joined in the round by Dazhong Investment, Youshi Capital and Tongsheng Capital.

Founded in 2008, Ankon has created a capsule endoscopy device that diagnoses gastric cancer at an earlier stage in order to increase a patient’s chances for survival.

The NaviCam system, which has received regulatory…